Initial Workup for a Swollen Joint

Clinical Assessment

The European League Against Rheumatism recommends a patient presenting with a swollen joint requires immediate clinical examination to detect synovitis, followed by a structured laboratory and imaging workup to differentiate inflammatory arthritis from infection, crystal arthropathy, or other causes—with urgent rheumatology referral within 6 weeks if inflammatory arthritis is suspected 1, 2
Document the presence of joint swelling associated with pain or stiffness, particularly morning stiffness lasting >30 minutes, as recommended by the American College of Rheumatology 2, 3
Perform a "squeeze test" for metacarpophalangeal (MCP) and metatarsophalangeal (MTP) joints to detect small joint involvement, as suggested by the European League Against Rheumatism 2, 3
Assess for trauma history, fever, systemic symptoms, and number of joints involved (monoarticular vs polyarticular), as recommended by the American College of Rheumatology 1

The American College of Rheumatology recommends inflammatory markers, such as C-reactive protein (CRP) and erythrocyte sedimentation rate (ESR), for diagnostic and prognostic information 1, 5
A complete blood count is essential to identify systemic inflammation and exclude infection or malignancy, as suggested by the European League Against Rheumatism 2, 5
Liver function tests (transaminases) and renal function tests are necessary to establish baseline and rule out hepatic or renal causes, as recommended by the American College of Rheumatology 2, 5
Urinalysis is crucial to identify renal involvement and exclude urinary tract infection, as suggested by the European League Against Rheumatism 2, 5
Rheumatoid factor (RF) and anti-citrullinated peptide antibodies (ACPA) have diagnostic and prognostic value in rheumatoid arthritis, as recommended by the American College of Rheumatology 1, 5
Antinuclear antibodies (ANA) are used to screen for systemic lupus erythematosus and other connective tissue diseases, as suggested by the European League Against Rheumatism 2, 5

The American College of Rheumatology recommends plain x-rays of affected joints to evaluate for erosions, joint damage, or metastatic lesions 1, 4, 5
Baseline radiographs are essential for monitoring structural progression, as suggested by the European League Against Rheumatism 5
Ultrasound with power Doppler is the preferred confirmatory test for detecting synovitis when clinical examination is uncertain, as recommended by the American College of Rheumatology 1, 2
MRI may be helpful if ultrasound and clinical examination remain inconclusive, as suggested by the European League Against Rheumatism 2, 4

The American College of Rheumatology recommends assessing the number of swollen and tender joints, elevated acute phase reactants (ESR/CRP), presence of RF and ACPA, and radiographic erosions on baseline imaging to stratify the risk of persistent disease 1, 6
These prognostic factors can help identify patients at high risk of persistent arthritis, as suggested by the European League Against Rheumatism 1, 6

The American College of Rheumatology recommends referring patients to a rheumatologist within 6 weeks of symptom onset for any patient with polyarticular swelling, positive inflammatory markers, or suspected inflammatory arthritis 1, 2, 3
Immediate referral is necessary if joint swelling (synovitis) persists >4 weeks or if there are signs of erosive disease, as suggested by the European League Against Rheumatism 4
Serial monitoring of disease activity at 1-3 month intervals using tender/swollen joint counts, patient and physician global assessments, and inflammatory markers is essential, as recommended by the American College of Rheumatology 1, 4

The American College of Rheumatology recommends symptomatic treatment with NSAIDs at the minimum effective dose for the shortest duration after evaluating gastrointestinal, renal, and cardiovascular risks 1
Intra-articular corticosteroid injections can be used for large joint oligoarthritis, but only after infection is excluded, as suggested by the European League Against Rheumatism 1, 4
Disease-modifying therapy, such as methotrexate, should be started within 3 months in patients at risk of persistent arthritis, as recommended by the American College of Rheumatology 1